Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression
These findings conclusively demonstrated that pharmacological inhibition of CSF-1R activity by ABSK021 resulted in significant anti-tumor effects in preclinical osteosarcoma models with CSF-1R overexpression. The high prevalence of CSF-1R expression observed in osteosarcoma patient samples highlights the potential clinical use of ABSK021, either as a monotherapy or in combination with chemotherapy, as a promising therapeutic strategy for osteosarcoma patients with CSF-1R as a potential predictive biomarker.
Authors
- Wan Shi (ORCID: https://orcid.org/0009-0005-2922-4627)
- Shuqun Yang (ORCID: https://orcid.org/0000-0002-8683-7738)
- Zhixuan Zhu
- Manqi Liu
- Dai Cheng
- Zhui Chen (ORCID: https://orcid.org/0009-0005-8600-3601)
- Shenyan Liu (ORCID: https://orcid.org/0009-0000-5494-163X)
- Cong Li (ORCID: https://orcid.org/0000-0002-2617-2455)
- Qi Zhang (ORCID: https://orcid.org/0000-0002-5055-3637)
- Jie Zhang (ORCID: https://orcid.org/0000-0003-0242-8812)
- Nannan Zhang (ORCID: https://orcid.org/0000-0002-0843-2401)
- Jie Wang (ORCID: https://orcid.org/0009-0009-3629-4542)
- Bin Shen (ORCID: https://orcid.org/0000-0002-4032-3280)
Institutions
- Io Therapeutics (United States) (US)
- ABB (Switzerland) (CH)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1186/s12967-025-06920-6
- Citations
- 2
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 1.61